The April 28, 2026 partial Schedule III order (91 Fed. Reg. 22714) did not merely lower marijuana’s scheduling classification.¹ It imposed a new federal compliance regime that effectively ended the low-overhead, cash-only state-only model that defined South Dakota’s medical cannabis program.²
Some public voices have offered vague assurances that “we’ll figure it out” for the past six months. That figure it out conversation occurred in May 2026 at the Cannabis Industry Association of South Dakota (CIASD) operator-only training.³
Two out-of-state firms—Canna Business Services (Pennsylvania) and 420 CFO / Laura Adams (Tennessee)—were brought in precisely because local leadership had not yet prepared operators for the federal overlay that was always the logical endpoint of rescheduling.⁴
What follows is a logical reconstruction of what these consultants most likely taught, based on the plain requirements of the April 28 order, standard DEA Schedule III compliance obligations, and the parallel public guidance issued by major law firms in the same period.⁵
The Non-Negotiable First Step: Expedited DEA Registration
The order created a narrow 60-day expedited registration window.⁶ Timely filers receive continued operation under their state license during DEA review and a six-month processing directive.⁷ Missing the window removes the safe harbor and places operators in the standard, higher-risk queue.⁸
Any competent consultant would have walked operators through the exact requirements: detailed security plans, responsible-person disclosures, background checks, SOPs, and facility diagrams.⁹ The message would have been unmistakable: filing is not optional. It is the price of admission to the 280E relief the industry is celebrating.
The Real Gatekeeper: cGMP and Pharmaceutical-Grade Standards
Schedule III now subjects qualifying products to federal controlled-substance manufacturing, distribution, recordkeeping, and traceability rules that increasingly mirror current Good Manufacturing Practice (cGMP) expectations.¹⁰ Most legacy South Dakota facilities were never designed for this level of control.
The consultants would have laid out the practical reality: full in-house compliance is capital-intensive. Selective retrofits focused on high-impact areas (traceability, security, labeling) combined with outsourcing manufacturing and testing to already-compliant partners is often the only viable path for smaller operators.¹¹
Financial Realities: 280E Relief Is Gated, Not Guaranteed
The tax windfall is real—but only for DEA-registered, compliant entities.¹² Treasury and IRS guidance on transition rules and possible retrospective relief is expected, yet the numbers remain clear: compliant operators could see hundreds of thousands in annual after-tax cash flow, while non-compliant operators receive zero relief and face elevated enforcement risk.¹³
Capital raising, banking access, and partnership structures are now the new credit gatekeepers.¹⁴
Strategic Options: The Survival Playbook
The training almost certainly presented four clear paths:
1. Full compliance retrofit (capital-heavy).
2. Strategic partnership, joint venture, or MSO affiliation.
3. Outsourcing manufacturing and distribution while retaining retail or branding.
4. Controlled exit or niche pivot (delivery-only, ancillary services) before a fire sale becomes inevitable.¹⁵
“Doing nothing” or waiting for additional state guidance would have been framed as the highest-risk strategy.¹⁶
South Dakota–Specific Realities
The consultants would have highlighted the limited state resources and guidance compared to mature markets.¹⁷ The very decision to import expertise from Pennsylvania and Tennessee was tacit acknowledgment of the local leadership vacuum. CIASD had to bring in outsiders because the operators who built the medical program had not prepared the industry for the federal reset.¹⁸
This closed-door approach is not an anomaly. For years, South Dakota cannabis influencers have conducted substantive policy discussions in secret meetings driven by personal connections rather than open tolerance for competing ideas. Patient voices have routinely been excluded from substantive discussions unless first pre-vetted and repurposed to serve business interests rather than genuine patient priorities. This culture of disrespecting varied perspectives produced a leadership class ill-equipped to command public discourse on federal law or administrative procedures. Had these influencers maintained rigorous research on federal exemption architecture and conformity mechanisms, they could have publicly commanded the discussion and immediately informed the patients they claim to serve. Instead, they were forced to catch up behind closed doors to avoid the public embarrassment of being visibly unprepared for the moment that has now arrived.¹⁹
In South Dakota, the sole author of the previously federally illegal state medical cannabis program privately told WeedPress that the failure of recreational cannabis at the ballot box had doomed most small operators from being able to remain financially solvent under the new federal compliance regime.²⁰ This candid admission, made outside public view, underscores the depth of the leadership vacuum and the failure to prepare the industry for the inevitable federal alignment that is now upon us.
The Policy Vacuum Exposed
This private briefing is the clearest evidence yet of the gap this publication has documented for months. While some public voices offered vague assurances, the professionals in the room delivered the unvarnished truth: the tax relief is real, but the compliance cliff is the real gatekeeper, and many legacy small operators will not clear it without decisive, immediate action.²¹
The consultants handed operators the map behind closed doors.
WeedPress, South Dakota’s only patient only watchdog advocacy organization, has now made that map public. Insiders wishing to clarify the record are invited to contact WeedPress through normal channels.
South Dakota operators—and the patients they serve—deserve more than slogans. They deserve the truth and the tools to survive the transition.
The choices are hard.
The time to act is now.
Footnotes
¹ Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements, 91 Fed. Reg. 22714 (Apr. 28, 2026).
² 21 U.S.C. § 823 (DEA registration authority).
³ Cannabis Industry Association of South Dakota (CIASD) operator-only training with Canna Business Services and 420 CFO, May 2026.
⁴ Id.
⁵ See Foley & Lardner, “Marijuana – Some Products Reclassified to Schedule III,” Apr. 23, 2026; KVK Lawyers, “The DOJ’s Cannabis Rescheduling Order,” May 1, 2026; Bloomberg Tax, Apr. 28, 2026.
⁶ 91 Fed. Reg. at 22714 (60-day expedited registration window).
⁷ Id. (safe-harbor provisions and six-month processing directive).
⁸ Id.
⁹ See Foley & Lardner and KVK Lawyers client alerts, supra note 5.
¹⁰ Federal registration, cGMP-like manufacturing, distribution, and recordkeeping obligations detailed in the April 28 order.
¹¹ Operator and consultant briefings on facility retrofits and outsourcing models.
¹² 21 U.S.C. § 823; 280E relief available only to compliant DEA registrants.
¹³ Headset and Vangst operator impact modeling, post-April 28, 2026.
¹⁴ Id.
¹⁵ Strategic options presented in CIASD training and parallel law-firm guidance.
¹⁶ Id.
¹⁷ South Dakota Department of Health and Board of Pharmacy guidance limitations relative to mature markets.
¹⁸ CIASD decision to import out-of-state expertise, May 2026.
¹⁹ WeedPress federal exemption architecture series, 2009–2026; Rapid City Post coverage, Apr. 23, 2026.
²⁰ Direct telephone verbal communication to WeedPress, May 2024, from the sole author of South Dakota’s original medical cannabis program (Initiated Measure 26).
²¹ Id.
WeedPress: The Paper Trail 
Leave a comment